IP Library Patent Application 15058390
Patent Application
App. No. 15/058,390

PROCESS FOR PREPARING OXYCODONE COMPOSITIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/058,390
Abstract

In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.

Claims (38)

1 - 79 . (canceled)

80 . A process for preparing an oxycodone salt composition, which process comprises steps of:

(a) hydrogenating a 14-hydroxycodeinone composition to obtain an oxycodone free base composition comprising 8α,14-dihydroxy-7,8-dihydrocodeinone;

(b) converting the oxycodone free base composition comprising 8α,14-dihydroxy-7,8-dihydrocodeinone to a first oxycodone salt composition comprising a first amount of 14-hydroxycodeinone; and

(c) hydrogenating the first oxycodone salt composition comprising the first amount of 14-hydroxycodeinone to a second oxycodone salt composition comprising a second amount of 14-hydroxycodeinone;

wherein the second amount of 14-hydroxycodeinone is lower than the first amount of 14-hydroxycodeinone.

81 . The process of claim 80 , wherein the process is for preparing an oxycodone hydrochloride salt composition.

82 . The process of claim 80 , wherein in step (b) the mixture is exposed to hydrogenation reagents for at least about 4 hours.

83 . The process of claim 82 , wherein in step (b) the mixture is exposed to the hydrogenation reagents for at least about 5 hours.

84 . The process of claim 83 , wherein in step (b) the mixture is exposed to the hydrogenation reagents for about 21 hours.

85 . The process of claim 80 , wherein the second oxycodone salt composition contains less than about 25 ppm 14-hydroxycodeinone.

86 . The process of claim 85 , wherein the second oxycodone salt composition contains less than about 15 ppm 14-hydroxycodeinone.

87 . The process of claim 86 , wherein the second oxycodone salt composition contains less than about 10 ppm 14-hydroxycodeinone.

88 . The process of claim 87 , wherein the second oxycodone salt composition contains less than about 5 ppm 14-hydroxycodeinone.

89 . The process of claim 80 , wherein at least some of 8α,14-dihydroxy-7,8-dihydrocodeinone in the oxycodone free base composition is converted to 14-hydroxycodeinone by an acid catalyzed dehydration consisting of conversion of 8α,14-dihydroxy-7,8-dihydrocodeinone to 14-hydroxycodeinone during step (b).

90 . The process of claim 80 , comprising preferentially removing 14-hydroxycodeinone from the first oxycodone salt composition or the second oxycodone salt composition.

91 . The process of claim 90 , wherein the 14-hydroxycodeinone is preferentially removed by exposing the first oxycodone salt composition or the second oxycodone salt composition to a substance that preferentially removes the 14-hydroxycodeinone compared to the oxycodone.

92 . The process of claim 91 , wherein the substance is a gel.

93 . The process of claim 91 , wherein the first oxycodone salt composition is passed through the substance that preferentially removes the 14-hydroxycodeinone.

94 . The process of claim 91 , wherein a slurry is formed with the oxycodone salt and the substance that preferentially removes the 14-hydroxycodeinone.

95 . The process of claim 91 , wherein step (c) is carried out at a temperature between about 40° C. to about 85° C.

96 . The process of claim 80 , comprising incubating the oxycodone free base composition comprising 8α,14-dihydroxy-7,8-dihydrocodeinone under conditions suitable to convert the oxycodone free base to the first oxycodone salt composition, wherein said conditions promote an acid catalyzed dehydration consisting of conversion of the 8α,14-dihydroxy-7,8-dihydrocodeinone to 14-hydroxycodeinone.

97 . The process of claim 80 , comprising isolating the second oxycodone salt composition.

98 . The process of claim 80 , wherein the second oxycodone salt composition comprises less than 100 ppm 14-hydroxycodeinone.

100 . The process of claim 98 , wherein the second oxycodone composition comprises less than 25 ppm of 14-hydroxycodeinone.

100 . The process of claim 100 , wherein the second oxycodone composition comprises less than 10 ppm of 14-hydroxycodeinone.

101 . The process of claim 98 , wherein the oxycodone salt composition comprises 1 ppm or more 14-hydroxycodeinone.

102 . A process for preparing an oxycodone salt composition, which process comprises steps of:

(a) hydrogenating a 14-hydroxycodeinone composition to obtain an oxycodone free base composition comprising 8α,14-dihydroxy-7,8-dihydrocodeinone;

(b) converting the oxycodone free base composition comprising 8α,14-dihydroxy-7,8-dihydrocodeinone to an oxycodone salt composition comprising an amount of 14-hydroxycodeinone; and

(c) hydrogenating the first oxycodone salt composition to a second oxycodone salt composition comprising a decreased amount of 14-hydroxycodeinone.

103 . The process of claim 102 , wherein the decreased amount is less than 100 ppm.

104 . The process of claim 103 , wherein the decreased amount is less than 25 ppm.

105 . The process of claim 104 , wherein the decreased amount is less than 10 ppm.

106 . The process of claim 103 , wherein the second oxycodone salt composition comprises 1 ppm or more 14-hydroxycodeinone.

107 . The process of claim 102 , comprising isolating the second oxycodone salt composition.

108 . The process of claim 102 , wherein the process is for preparing an oxycodone hydrochloride salt composition comprising less than 25 ppm 14-hydroxycodeinone.

109 . The process of claim 108 , wherein the oxycodone salt composition comprises 1 ppm or more 14-hydroxycodeinone.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2019
From: THE P.F. LABORATORIES, INC.; PURDUE PHARMA TECHNOLOGIES, INC.
To: PURDUE PHARMA L.P.
Reel/Frame 048936/0093 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2016
From: CHAPMAN, ROBERT; RIDER, LONN S.; HONG, QI; KYLE, DONALD; KUPPER, ROBERT
To: EURO-CELTIQUE S.A.
Reel/Frame 040033/0650 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2016
From: EURO-CELTIQUE S.A.
To: PURDUE PHARMA L.P.
Reel/Frame 040034/0100 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2016
From: PURDUE PHARMA L.P.
To: PURDUE PHARMA L.P.; THE P.F. LABORATORIES, INC.; PURDUE PHARMACEUTICALS L.P.; RHODES TECHNOLOGIES
Reel/Frame 040034/0442 →